-
Je něco špatně v tomto záznamu ?
Russian VX: inhibition and reactivation of acetylcholinesterase compared with VX agent
Kuca K., Jun D., Cabal J., Hrabinova M., Bartosova L., Opletalova V.
Jazyk angličtina Země Dánsko
NLK
Medline Complete (EBSCOhost)
od 2004-01-01 do Před 1 rokem
Wiley Online Library (archiv)
od 1997-01-01 do 2012-12-31
- MeSH
- chemické bojové látky toxicita MeSH
- cholinesterasové inhibitory toxicita MeSH
- financování organizované MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- mozek enzymologie účinky léků MeSH
- organothiofosforové sloučeniny toxicita MeSH
- oximy farmakologie MeSH
- prasata MeSH
- reaktivátory cholinesterasy farmakologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- zvířata MeSH
Organophosphorus compounds such as nerve agents inhibit, practically irreversibly, cholinesterases by their phosphorylation in the active site of these enzymes. Current antidotal treatment used in the case of acute nerve agent intoxications consists of combined administration of anticholinergic drug (usually atropine) and acetylcholinesterase (AChE, EC 3.1.1.7) reactivator (HI-6, obidoxime, pralidoxime), which from a chemical view is a derivative from the group of pyridinium or bispyridinium aldoximes (commonly called "oxime"). Oximes counteract acetylcholine increase, resulting from AChE inhibition. In the human body environment these compounds are powerful nucleophiles and are able to break down the bond between AChE and nerve agent molecule. This process leads to renewal of enzyme functionality -- to its reactivation. The usefulness of oxime in the reactivation process depends on its chemical structure and on the nerve agent whereby AChE is inhibited. Due to this fact, selection of suitable reactivator in the treatment of intoxications is very important. In our work, we have compared differences in the in vitro inhibition potency of VX and Russian VX on rat, pig and human brain, and subsequently we have tested reactivation of rat brain cholinesterase inhibited by these agents using oxime HI-6, obidoxime, pralidoxime, trimedoxime and methoxime. The results showed that no major differences in the reactivation process of both VX and Russian VX-inhibited cholinesterase. The similarity in reactivation was caused by analogous chemical structure of either nerve agent; and that oxime HI-6 seems to be the most effective reactivator tested, which confirms that HI-6 is currently the most potent reactivator of AChE inhibited by nerve agents. The results obtained in our study should be considered in the future development of new AChE reactivators.
Citace poskytuje Crossref.org
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07525128
- 003
- CZ-PrNML
- 005
- 20130101154331.0
- 008
- 090616s2006 dk e eng||
- 009
- AR
- 024 __
- $a 10.1111/j.1742-7843.2006.pto_267.x $2 doi
- 035 __
- $a (PubMed)16623863
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a dk
- 100 1_
- $a Kuča, Kamil, $d 1978- $7 xx0041831
- 245 10
- $a Russian VX: inhibition and reactivation of acetylcholinesterase compared with VX agent / $c Kuca K., Jun D., Cabal J., Hrabinova M., Bartosova L., Opletalova V.
- 314 __
- $a Department of Toxicology, Faculty of Military Health Sciences, University of Defence, 50001 Hradec Kralove, Czech Republic. kucakam@pmfhk.cz
- 520 9_
- $a Organophosphorus compounds such as nerve agents inhibit, practically irreversibly, cholinesterases by their phosphorylation in the active site of these enzymes. Current antidotal treatment used in the case of acute nerve agent intoxications consists of combined administration of anticholinergic drug (usually atropine) and acetylcholinesterase (AChE, EC 3.1.1.7) reactivator (HI-6, obidoxime, pralidoxime), which from a chemical view is a derivative from the group of pyridinium or bispyridinium aldoximes (commonly called "oxime"). Oximes counteract acetylcholine increase, resulting from AChE inhibition. In the human body environment these compounds are powerful nucleophiles and are able to break down the bond between AChE and nerve agent molecule. This process leads to renewal of enzyme functionality -- to its reactivation. The usefulness of oxime in the reactivation process depends on its chemical structure and on the nerve agent whereby AChE is inhibited. Due to this fact, selection of suitable reactivator in the treatment of intoxications is very important. In our work, we have compared differences in the in vitro inhibition potency of VX and Russian VX on rat, pig and human brain, and subsequently we have tested reactivation of rat brain cholinesterase inhibited by these agents using oxime HI-6, obidoxime, pralidoxime, trimedoxime and methoxime. The results showed that no major differences in the reactivation process of both VX and Russian VX-inhibited cholinesterase. The similarity in reactivation was caused by analogous chemical structure of either nerve agent; and that oxime HI-6 seems to be the most effective reactivator tested, which confirms that HI-6 is currently the most potent reactivator of AChE inhibited by nerve agents. The results obtained in our study should be considered in the future development of new AChE reactivators.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mozek $x enzymologie $x účinky léků $7 D001921
- 650 _2
- $a chemické bojové látky $x toxicita $7 D002619
- 650 _2
- $a cholinesterasové inhibitory $x toxicita $7 D002800
- 650 _2
- $a reaktivátory cholinesterasy $x farmakologie $7 D002801
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a organothiofosforové sloučeniny $x toxicita $7 D009946
- 650 _2
- $a oximy $x farmakologie $7 D010091
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a prasata $7 D013552
- 700 1_
- $a Jun, Daniel, $d 1976- $7 xx0040498
- 700 1_
- $a Cabal, Jiří, $d 1957- $7 mzk2003181397
- 700 1_
- $a Hrabinová, Martina $7 xx0118798
- 700 1_
- $a Bartošová, Lucie, $d 1977- $7 xx0041840
- 700 1_
- $a Opletalová, Veronika, $d 1955- $7 jn20000620259
- 773 0_
- $w MED00007578 $t Basic & clinical pharmacology & toxicology $g Roč. 98, č. 4 (2006), s. 389-394 $x 1742-7835
- 910 __
- $a ABA008 $b x $y 8
- 990 __
- $a 20090310084605 $b ABA008
- 991 __
- $a 20130101154514 $b ABA008
- 999 __
- $a ok $b bmc $g 661885 $s 518623
- BAS __
- $a 3
- BMC __
- $a 2006 $b 98 $c 4 $d 389-394 $i 1742-7835 $m Basic & clinical pharmacology & toxicology $x MED00007578
- LZP __
- $a 2009-B4/ipme